Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGORA-1 / ALFA 2100: Gemtuzumab ozogamicin + gilteritinib in FLT3-ITD relapsed/refractory AML
2021-001813-35Phase 2Active
- Sponsor
- Centre Antoine Lacassagne
- Start
- Jan 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of gilteritinib and gemtuzumab ozogamicin in acute myeloid leukemia (AML), sponsored by Centre Antoine Lacassagne. Primary endpoint: Safety of adding gilteritinib to AGORA treatment platform. Started Jan 2022; status: active.
02
Drugs
gilteritinibgemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2021-001813-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001813-35.